癌症研究
克拉斯
腺癌
转移
生物
医学
癌症
内科学
结直肠癌
作者
Xiong Chen,Yujie Zhao,Daxuan Wang,Ying Lin,Jihuan Hou,Xiaolin Xu,Jianben Wu,Linhai Zhong,Yitong Zhou,Jinying Shen,Wenqing Zhang,Hanwei Cao,Xiaoting Hong,Tianhui Hu,Yan-yan Zhan
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-10-15
卷期号:81 (23): 5904-5918
被引量:16
标识
DOI:10.1158/0008-5472.can-21-0980
摘要
Invasive mucinous lung adenocarcinoma (IMA) is a subtype of lung adenocarcinoma with a strong invasive ability. IMA frequently carries "undruggable" KRAS mutations, highlighting the need for new molecular targets and therapies. Nuclear receptor HNF4α is abnormally enriched in IMA, but the potential of HNF4α to be a therapeutic target for IMA remains unknown. Here, we report that P2 promoter-driven HNF4α expression promotes IMA growth and metastasis. Mechanistically, HNF4α transactivated lncRNA BC200, which acted as a scaffold for mRNA binding protein FMR1. BC200 promoted the ability of FMR1 to bind and regulate stability of cancer-related mRNAs and HNF4α mRNA, forming a positive feedback circuit. Mycophenolic acid, the active metabolite of FDA-approved drug mycophenolate mofetil, was identified as an HNF4α antagonist exhibiting anti-IMA activities in vitro and in vivo. This study reveals the role of a HNF4α-BC200-FMR1-positive feedback loop in promoting mRNA stability during IMA progression and metastasis, providing a targeted therapeutic strategy for IMA. SIGNIFICANCE: Growth and metastatic progression of invasive mucinous lung adenocarcinoma can be restricted by targeting HNF4α, a critical regulator of a BC200-FMR1-mRNA stability axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI